DE19728516C2 - TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol - Google Patents
TTS zur Verabreichung von Levonorgestrel und gegebenenfalls EstradiolInfo
- Publication number
- DE19728516C2 DE19728516C2 DE19728516A DE19728516A DE19728516C2 DE 19728516 C2 DE19728516 C2 DE 19728516C2 DE 19728516 A DE19728516 A DE 19728516A DE 19728516 A DE19728516 A DE 19728516A DE 19728516 C2 DE19728516 C2 DE 19728516C2
- Authority
- DE
- Germany
- Prior art keywords
- tts
- skin
- levonorgestrel
- percent
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 title claims abstract description 20
- 229960004400 levonorgestrel Drugs 0.000 title claims abstract description 20
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims description 19
- 229960005309 estradiol Drugs 0.000 title claims description 17
- 229930182833 estradiol Natural products 0.000 title claims description 15
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000003270 steroid hormone Substances 0.000 claims abstract description 13
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims description 38
- 239000011159 matrix material Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 19
- 239000013543 active substance Substances 0.000 claims description 17
- 229920001577 copolymer Polymers 0.000 claims description 11
- 150000003431 steroids Chemical class 0.000 claims description 9
- -1 citric acid triester Chemical class 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000002313 adhesive film Substances 0.000 claims description 4
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 4
- 238000001125 extrusion Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000007933 dermal patch Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 8
- 239000002904 solvent Substances 0.000 abstract description 6
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 2
- 229940100640 transdermal system Drugs 0.000 abstract 2
- 239000010410 layer Substances 0.000 description 35
- 230000001070 adhesive effect Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000853 adhesive Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229920000193 polymethacrylate Polymers 0.000 description 8
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 239000000583 progesterone congener Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000012790 adhesive layer Substances 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008646 thermal stress Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- ZVVGLAMWAQMPDR-WVEWYJOQSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;hydrate Chemical compound O.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 ZVVGLAMWAQMPDR-WVEWYJOQSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000004840 adhesive resin Substances 0.000 description 1
- 229920006223 adhesive resin Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960003851 estradiol hemihydrate Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical group CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19728516A DE19728516C2 (de) | 1997-07-04 | 1997-07-04 | TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol |
| IL13376298A IL133762A0 (en) | 1997-07-04 | 1998-07-02 | Transdermal therapeutic system (tts) for the administration of levonorgestral |
| CA002294788A CA2294788C (en) | 1997-07-04 | 1998-07-02 | Therapeutical system for transdermal delivery of levonorgestrel |
| JP50634599A JP2002510315A (ja) | 1997-07-04 | 1998-07-02 | レボノルゲストレルを投与するための経皮吸収治療システム（ｔｔｓ） |
| NZ502351A NZ502351A (en) | 1997-07-04 | 1998-07-02 | Transdermal therapeutical system for delivery of levonorgestrel |
| ES98939602T ES2197495T3 (es) | 1997-07-04 | 1998-07-02 | Sistema terapeutico transdermico (tts), que contiene polimeros de poli (met) acrilato con un contenido de grupos de amonio, destinado a la administracion de levonorgestrel. |
| KR10-2000-7000017A KR100381997B1 (ko) | 1997-07-04 | 1998-07-02 | 레보노르게스트렐의 투여를 위한 경피적 치료학적 시스템 |
| US09/462,009 US6555131B1 (en) | 1997-07-04 | 1998-07-02 | Therapeutical system for transdermal delivery of levonorgestrel |
| PCT/EP1998/004079 WO1999001109A2 (de) | 1997-07-04 | 1998-07-02 | Transdermales therapeutisches system (tts) zur verabreichung von levonorgestrel |
| CN98808863A CN1269717A (zh) | 1997-07-04 | 1998-07-02 | 供左炔诺孕酮给药用的透皮治疗系统(tts) |
| DE59807891T DE59807891D1 (de) | 1997-07-04 | 1998-07-02 | Transdermales therapeutisches system (tts) enthaltend ammoniogruppenhaltige (meth)acrylatpolymere zur verabreichung von levonorgestrel |
| AU88055/98A AU749326B2 (en) | 1997-07-04 | 1998-07-02 | Therapeutical system for transdermal delivery of levonorgestrel |
| DK98939602T DK1003477T3 (da) | 1997-07-04 | 1998-07-02 | Transdermalt terapeutisk system (TTS) indeholdende ammoniogruppeholdige (meth)acrylatpolymerer til administration af levonorgestrel |
| AT98939602T ATE236623T1 (de) | 1997-07-04 | 1998-07-02 | Transdermales therapeutisches system (tts) enthaltend ammoniogruppenhaltige (meth)acrylatpolymere zur verabreichung von levonorgestrel |
| EP98939602A EP1003477B1 (de) | 1997-07-04 | 1998-07-02 | Transdermales therapeutisches system (tts) enthaltend ammoniogruppenhaltige (meth)acrylatpolymere zur verabreichung von levonorgestrel |
| BR9815510-5A BR9815510A (pt) | 1997-07-04 | 1998-07-02 | Sistema terapêutico transdérmico (tts), para a administração transcutânea de esteróides sexuais e método para produção em um tts |
| PT98939602T PT1003477E (pt) | 1997-07-04 | 1998-07-02 | Sistema terapeutico transdermico (tts), contendo polimeros de (met)acrilato com grupos amonio para administracao de levonorgestrel |
| ZA985863A ZA985863B (en) | 1997-07-04 | 1998-07-03 | Transdermal therapeutic system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19728516A DE19728516C2 (de) | 1997-07-04 | 1997-07-04 | TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19728516A1 DE19728516A1 (de) | 1999-01-07 |
| DE19728516C2 true DE19728516C2 (de) | 1999-11-11 |
Family
ID=7834590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19728516A Expired - Fee Related DE19728516C2 (de) | 1997-07-04 | 1997-07-04 | TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol |
| DE59807891T Expired - Fee Related DE59807891D1 (de) | 1997-07-04 | 1998-07-02 | Transdermales therapeutisches system (tts) enthaltend ammoniogruppenhaltige (meth)acrylatpolymere zur verabreichung von levonorgestrel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59807891T Expired - Fee Related DE59807891D1 (de) | 1997-07-04 | 1998-07-02 | Transdermales therapeutisches system (tts) enthaltend ammoniogruppenhaltige (meth)acrylatpolymere zur verabreichung von levonorgestrel |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6555131B1 (ko) |
| EP (1) | EP1003477B1 (ko) |
| JP (1) | JP2002510315A (ko) |
| KR (1) | KR100381997B1 (ko) |
| CN (1) | CN1269717A (ko) |
| AT (1) | ATE236623T1 (ko) |
| AU (1) | AU749326B2 (ko) |
| BR (1) | BR9815510A (ko) |
| CA (1) | CA2294788C (ko) |
| DE (2) | DE19728516C2 (ko) |
| DK (1) | DK1003477T3 (ko) |
| ES (1) | ES2197495T3 (ko) |
| IL (1) | IL133762A0 (ko) |
| NZ (1) | NZ502351A (ko) |
| PT (1) | PT1003477E (ko) |
| WO (1) | WO1999001109A2 (ko) |
| ZA (1) | ZA985863B (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19918106A1 (de) | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern |
| FR2795326B1 (fr) * | 1999-06-28 | 2001-08-31 | Adir | Composition pharmaceutique solide thermoformable a liberation controlee |
| NZ572206A (en) * | 2006-03-24 | 2012-02-24 | Auxilium Int Holdings Inc | Process for the preparation of a hot-melt extruded laminate |
| US8173152B2 (en) | 2006-03-24 | 2012-05-08 | Auxilium Us Holdings, Llc | Stabilized compositions containing alkaline labile drugs |
| US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
| HUP0900698A2 (en) * | 2009-11-06 | 2011-06-28 | Richter Gedeon Nyrt | Pharmaceutical compositions of enhanced stability containing drospirenone and ethynyl estradiol and process for their preparation |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0399432A2 (en) * | 1989-05-25 | 1990-11-28 | Takeda Chemical Industries, Ltd. | Transdermal therapeutic composition |
| EP0563507A1 (en) * | 1992-04-01 | 1993-10-06 | Mli Acquisition Corp. Ii | Transdermal patch incorporating a polymer film incorporated with an active agent |
| DE4310012A1 (de) * | 1993-03-27 | 1994-09-29 | Roehm Gmbh | Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung |
| DE4332094A1 (de) * | 1993-09-22 | 1995-03-23 | Lohmann Therapie Syst Lts | Lösemittelfrei herstellbares Wirkstoffpflaster |
| WO1996008229A2 (en) * | 1994-09-14 | 1996-03-21 | Minnesota Mining And Manufacturing Company | Matrix for transdermal drug delivery |
| WO1996008255A1 (en) * | 1994-09-14 | 1996-03-21 | Minnesota Mining And Manufacturing Company | Transdermal device for delivery of levonorgestrel |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3823070A1 (de) | 1988-07-07 | 1990-02-22 | Kettelhack Riker Pharma Gmbh | Selbstklebendes heftpflaster |
| DE19526864A1 (de) * | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
| AU728120B2 (en) * | 1996-03-25 | 2001-01-04 | Lts Lohmann Therapie-Systeme Gmbh | A Transdermal therapeutic system with small application thickness and high flexibility, as well as processes for its production |
| US5762956A (en) * | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| DE19653605C2 (de) | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems |
-
1997
- 1997-07-04 DE DE19728516A patent/DE19728516C2/de not_active Expired - Fee Related
-
1998
- 1998-07-02 AU AU88055/98A patent/AU749326B2/en not_active Ceased
- 1998-07-02 NZ NZ502351A patent/NZ502351A/xx unknown
- 1998-07-02 DE DE59807891T patent/DE59807891D1/de not_active Expired - Fee Related
- 1998-07-02 WO PCT/EP1998/004079 patent/WO1999001109A2/de active IP Right Grant
- 1998-07-02 IL IL13376298A patent/IL133762A0/xx not_active IP Right Cessation
- 1998-07-02 PT PT98939602T patent/PT1003477E/pt unknown
- 1998-07-02 DK DK98939602T patent/DK1003477T3/da active
- 1998-07-02 AT AT98939602T patent/ATE236623T1/de not_active IP Right Cessation
- 1998-07-02 ES ES98939602T patent/ES2197495T3/es not_active Expired - Lifetime
- 1998-07-02 JP JP50634599A patent/JP2002510315A/ja not_active Ceased
- 1998-07-02 US US09/462,009 patent/US6555131B1/en not_active Expired - Fee Related
- 1998-07-02 BR BR9815510-5A patent/BR9815510A/pt not_active IP Right Cessation
- 1998-07-02 CN CN98808863A patent/CN1269717A/zh active Pending
- 1998-07-02 KR KR10-2000-7000017A patent/KR100381997B1/ko not_active IP Right Cessation
- 1998-07-02 EP EP98939602A patent/EP1003477B1/de not_active Expired - Lifetime
- 1998-07-02 CA CA002294788A patent/CA2294788C/en not_active Expired - Fee Related
- 1998-07-03 ZA ZA985863A patent/ZA985863B/xx unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0399432A2 (en) * | 1989-05-25 | 1990-11-28 | Takeda Chemical Industries, Ltd. | Transdermal therapeutic composition |
| EP0563507A1 (en) * | 1992-04-01 | 1993-10-06 | Mli Acquisition Corp. Ii | Transdermal patch incorporating a polymer film incorporated with an active agent |
| DE4310012A1 (de) * | 1993-03-27 | 1994-09-29 | Roehm Gmbh | Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung |
| DE4332094A1 (de) * | 1993-09-22 | 1995-03-23 | Lohmann Therapie Syst Lts | Lösemittelfrei herstellbares Wirkstoffpflaster |
| WO1996008229A2 (en) * | 1994-09-14 | 1996-03-21 | Minnesota Mining And Manufacturing Company | Matrix for transdermal drug delivery |
| WO1996008255A1 (en) * | 1994-09-14 | 1996-03-21 | Minnesota Mining And Manufacturing Company | Transdermal device for delivery of levonorgestrel |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1003477B1 (de) | 2003-04-09 |
| BR9815510A (pt) | 2002-02-05 |
| AU749326B2 (en) | 2002-06-20 |
| DE59807891D1 (de) | 2003-05-15 |
| ATE236623T1 (de) | 2003-04-15 |
| KR20010021495A (ko) | 2001-03-15 |
| CN1269717A (zh) | 2000-10-11 |
| PT1003477E (pt) | 2003-08-29 |
| WO1999001109A2 (de) | 1999-01-14 |
| AU8805598A (en) | 1999-01-25 |
| EP1003477A2 (de) | 2000-05-31 |
| DE19728516A1 (de) | 1999-01-07 |
| KR100381997B1 (ko) | 2003-04-26 |
| DK1003477T3 (da) | 2003-07-28 |
| ES2197495T3 (es) | 2004-01-01 |
| NZ502351A (en) | 2002-09-27 |
| IL133762A0 (en) | 2001-04-30 |
| US6555131B1 (en) | 2003-04-29 |
| WO1999001109A3 (de) | 1999-03-25 |
| JP2002510315A (ja) | 2002-04-02 |
| CA2294788C (en) | 2005-06-21 |
| CA2294788A1 (en) | 1999-01-14 |
| ZA985863B (en) | 1998-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19728516C2 (de) | TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol | |
| DE19728517C2 (de) | TTS zur Verabreichung von Sexualsteroidhormonen und Verfahren zu seiner Herstellung | |
| DE4336557C2 (de) | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung | |
| EP0186019B1 (de) | Wirkstoffpflaster | |
| EP0744944B1 (de) | Transdermale therapeutische systeme enthaltend sexualsteroide | |
| DE19821788C1 (de) | Transdermales Therapeutisches System (TTS) Pergolid enthaltend | |
| EP0695177B1 (de) | Wirkstoffplaster | |
| EP0802789B1 (de) | Estradiolhaltiges pflaster | |
| EP0659081B1 (de) | Dexpanthenol-haltiges pflaster zur transdermalen applikation von steroidhormonen | |
| DE19906152B4 (de) | Wirkstoffhaltige Laminate für Transdermalsysteme | |
| WO1998031349A1 (de) | Transdermales therapeutisches system zur abgabe von hormonen | |
| EP1448175A1 (de) | Steroidhormonhaltige transdermale therapeutische systeme enthaltend propylenglycolmonocaprylat | |
| DE19812413C1 (de) | Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend | |
| DE10118282A1 (de) | Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke | |
| DE3823070A1 (de) | Selbstklebendes heftpflaster | |
| MXPA00000065A (en) | Therapeutical system for transdermal delivery of levonorgestrel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |